The purpose of this study is to determine whether the addition of the agent, pembrolizumab (Keytruda) to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed I-II endometrial cancer that is . NOTE: This study is no longer enrolling.

This Study is Open To:

This study is no longer enrolling.

This Study is NOT Open To:

This study is no longer enrolling.

Study Contact Information:

Principal Investigator: Floor Backes

For additional information: Use the contacts listed per each study location.

Study Contact Information:

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Study Contact Information:

About the Study

This Study is Open To:

This Study is NOT Open To:

Study Contact Information:

Knowledge Can Save Lives